PPARs in Irradiation-Induced Gastrointestinal Toxicity
- PMID: 20037741
- PMCID: PMC2796461
- DOI: 10.1155/2010/528327
PPARs in Irradiation-Induced Gastrointestinal Toxicity
Abstract
The use of radiation therapy to treat cancer inevitably involves exposure of normal tissues. Although the benefits of this treatment are well established, many patients experience distressing complications due to injury to normal tissue. These side effects are related to inflammatory processes, and they decrease therapeutic benefit by increasing the overall treatment time. Emerging evidence indicates that PPARs and their ligands are important in the modulation of immune and inflammatory reactions. This paper discusses the effects of abdominal irradiation on PPARs, their role and functions in irradiation toxicity, and the possibility of using their ligands for radioprotection.
References
-
- Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. The Lancet Oncology. 2007;8(11):1007–1017. - PubMed
-
- Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46(8):1319–1327. - PubMed
-
- Baldwin AS., Jr. The NF-κ B and Iκ B proteins: new discoveries and insights. Annual Review of Immunology. 1996;14:649–683. - PubMed
LinkOut - more resources
Full Text Sources
